Phenothiazine‐based chalcones as potential dual‐target inhibitors towards cholinesterases (AChE, BuChE) and Monoamine Oxidases (MAO‐A, MAO‐B)     
Yazarlar (10)
Cem Yamali
Atatürk Üniversitesi, Türkiye
Feyza Sena Engin
Atatürk Üniversitesi, Türkiye
Sinan Bilginer
Atatürk Üniversitesi, Türkiye
Doç. Dr. Mehtap TUĞRAK SAKARYA Atatürk Üniversitesi, Türkiye
Dilan Ozmen Ozgun
Aǧrı İbrahim Çeçen Üniversitesi, Türkiye
Gulsen Ozli
Erzincan Binali Yıldırım Üniversitesi, Türkiye
Serkan Levent
Anadolu Üniversitesi, Türkiye
Begum Nurpelin Saglik
Anadolu Üniversitesi, Türkiye
Yusuf Ozkay
Anadolu Üniversitesi, Türkiye
Halise Inci Gul
Atatürk Üniversitesi, Türkiye
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale
Dergi Adı Journal of Heterocyclic Chemistry
Dergi ISSN 0022-152X Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q3
Makale Dili İngilizce
Basım Tarihi 01-2021
Cilt No 58
Sayı 1
Sayfalar 161 / 171
DOI Numarası 10.1002/jhet.4156
Özet
Chalcones targeting neurodegenerative diseases have been known as attractive structures in drug design and discovery. In this study, phenothiazine-based chalcones as ChEs and MAOs inhibitors were designed and synthesized via base-catalyzed Claisen-Schmidt condensation, and chemical structures of the compounds were elucidated by NMRs and HRMS. Compounds 3 and 9 showed promising inhibition potency against AChE enzyme with IC50 values of 0.221 μM and 0.053 μM while compound 9 displayed remarkable inhibition potency toward MAO-B enzyme with IC50 value of 0.048 μM. Compound 9, as a dual-target inhibitor, selectively inhibited AChE and MAO-B enzymes. This promising behavior is an advantage for the compound since MAO-B and AChE inhibition have a role in Alzheimer's disease. Fused tricyclic ring systems such as phenothiazine incorporated with chalcone moiety being multitargeting ligands may help scientists for the rational design of novel lead compounds targeting neurodegenerative illnesses.
Anahtar Kelimeler